Figure S1. Proportions of patients experiencing CIDs in the ECLIPSE study. (EPS 1962 kb
Table S1. Evaluation of the reproducibility of measurements during the follow-up period. (DOCX 17 kb
Rank probability analysis of FEV1% with using statins in COPD patients. (TIF 36014 kb
Figure S1. 15-point Global Rating of Change anchor question used at each follow-up moment. Figure S2...
Table S1. Patient demographics and baseline characteristics (ECLIPSE study). Table S2. Long-term out...
Results tables for sensitivity analyses testing the assumptions made in the main analysis (as descri...
Additional file 1: Figure S1. Flowchart of patient selection. Table S1. Codes used for identificatio...
Table S1. Baseline characteristics by treatment group for patients included in this analysis and for...
Association Between Biomarkers and COPD Outcomes. Table S2. Statistical Models. Table S3. Demographi...
Table S1. Characteristics of ECLIPSE Study COPD cases stratified by BMI category. Continuous variabl...
Table S1. Demographics of patients without COPD. Table S2. Demographics of patients with COPD. Table...
Forest plot showing effect of statins on heart disease-related mortality in COPD patients. (TIF 3953...
Weighted linear regression bubble plots for associations (study end) with percentage of rescue-free ...
Fig S1. Kaplan–Meier curves and Cox proportional hazard model on time to first moderate-to-severe CO...
Rank probability analysis of FEV1/FVC% with using statins in COPD patients. (TIF 36014 kb
Table S1. Ten-Year CVD Risk by GOLD classification and selected baseline characteristics in COPD pat...
Table S1. Evaluation of the reproducibility of measurements during the follow-up period. (DOCX 17 kb
Rank probability analysis of FEV1% with using statins in COPD patients. (TIF 36014 kb
Figure S1. 15-point Global Rating of Change anchor question used at each follow-up moment. Figure S2...
Table S1. Patient demographics and baseline characteristics (ECLIPSE study). Table S2. Long-term out...
Results tables for sensitivity analyses testing the assumptions made in the main analysis (as descri...
Additional file 1: Figure S1. Flowchart of patient selection. Table S1. Codes used for identificatio...
Table S1. Baseline characteristics by treatment group for patients included in this analysis and for...
Association Between Biomarkers and COPD Outcomes. Table S2. Statistical Models. Table S3. Demographi...
Table S1. Characteristics of ECLIPSE Study COPD cases stratified by BMI category. Continuous variabl...
Table S1. Demographics of patients without COPD. Table S2. Demographics of patients with COPD. Table...
Forest plot showing effect of statins on heart disease-related mortality in COPD patients. (TIF 3953...
Weighted linear regression bubble plots for associations (study end) with percentage of rescue-free ...
Fig S1. Kaplan–Meier curves and Cox proportional hazard model on time to first moderate-to-severe CO...
Rank probability analysis of FEV1/FVC% with using statins in COPD patients. (TIF 36014 kb
Table S1. Ten-Year CVD Risk by GOLD classification and selected baseline characteristics in COPD pat...
Table S1. Evaluation of the reproducibility of measurements during the follow-up period. (DOCX 17 kb
Rank probability analysis of FEV1% with using statins in COPD patients. (TIF 36014 kb
Figure S1. 15-point Global Rating of Change anchor question used at each follow-up moment. Figure S2...
DOI
Add to ORKG